A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs

Completed · Phase 2

Conditions studied: HIV Infections

In brief

To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.

Key facts

Study ID

NCT00002332

Run by

Immunobiology Research Institute

People needed

60

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Asymptomatic or minimally symptomatic HIV infection (no evidence of AIDS).
• CD4 count <= 400 cells/mm3 within 6 weeks prior to study entry (CD4 count changed to 100 - 400 cells/mm3 per amendment).
• Tolerated the current nucleoside analog antiretroviral treatment for at least 4 weeks prior to study entry.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Known hypersensitivity to thymopentin or any component of the formulation.
• Significant chronic underlying medical illness that would impede study participation.
• Grade 2 or higher peripheral neuropathy related to nucleoside analog antiretroviral treatment.
• Concurrent Medication:
• Excluded:
• Any antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine.
• HIV vaccines or any investigational or non-FDA approved medication or immunomodulatory or experimental therapy within 30 days prior to study entry.
• Patients with the following prior condition are excluded:
• Abnormal chest x-ray consistent with active opportunistic infection within 6 weeks prior to study entry.
• Prior Medication:
• Excluded:
• Any prior antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine within 30 days prior to study entry.
• Required:
• Current nucleoside analog antiretroviral treatment.
• Required:
• Nucleoside analog antiretroviral treatment for at least 4 weeks prior to study entry.
• Significant active alcohol or drug abuse sufficient to prevent study compliance.

Where it is running

• Dr Marcus Conant — San Francisco, California, United States
• Dr Jeffrey Galpin — Tarzana, California, United States
• Novum Inc — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.